Developing an AAV-Based Gene Replacement Therapy for Mitochondrial Alanyl-tRNA Synthetase 2 (AARS2) Leukodystrophy

被引：0
|
作者：
Xing, Ruxiao [1 ]
Ren, Lingzhi [1 ]
Liu, Nan [1 ]
Zhou, Chen [1 ]
Liang, Jialing [1 ]
Wang, Jiaming [1 ,2 ]
Gao, Guangping [1 ,2 ]
Wang, Dan [1 ,3 ]
机构：
[1] Univ Massachusetts, Chan Med Sch, Horae Gene Therapy Ctr, Worcester, MA 01605 USA
[2] Univ Massachusetts, Dept Microbiol & Physiol Syst, Chan Med Sch, Worcester, MA 01605 USA
[3] Univ Massachusetts, RNA Therapeut Inst, Chan Med Sch, Worcester, MA 01605 USA
来源：
MOLECULAR THERAPY | 2024年 / 32卷 / 04期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
36
引用
收藏
页码：20 / 20
页数：1
相关论文
共 50 条
  • [41] Gene therapy platform for bone regeneration using an exogenously regulated, AAV-2-based gene expression system
    Gafni, Y
    Pelled, G
    Zilberman, Y
    Turgeman, G
    Apparailly, F
    Yotvat, H
    Galun, E
    Gazit, Z
    Jorgensen, C
    Gazit, D
    MOLECULAR THERAPY, 2004, 9 (04) : 587 - 595
  • [42] A tropism modified AAV2-based vector system for gene therapy of peritoneal ovarian carcinoma
    Shi, WF
    Arnold, G
    Bartlett, JS
    MOLECULAR THERAPY, 2003, 7 (05) : S43 - S43
  • [43] Long-term evaluation of retinal function in Prph2Rd2/Rd2 mice following AAV-mediated gene replacement therapy
    Schlichtenbrede, FC
    da Cruz, L
    Stephens, C
    Smith, AJ
    Georgiadis, A
    Thrasher, AJ
    Bainbridge, JWB
    Seeliger, MW
    Ali, RR
    JOURNAL OF GENE MEDICINE, 2003, 5 (09): : 757 - 764
  • [44] A novel compound heterozygous mutation in AARS2 gene (c.965 G > A, p.R322H; c.334 G > C, p.G112R) identified in a Chinese patient with leukodystrophy involved in brain and spinal cord
    Chengyuan Song
    Linliu Peng
    Shengjun Wang
    Yiming Liu
    Journal of Human Genetics, 2019, 64 : 979 - 983
  • [45] TOWARDS DEVELOPING HIV-2 BASED RETROVIRAL VECTORS FOR GENE-THERAPY
    GARZINODEMO, A
    GALLO, RC
    ARYA, SK
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1994, 10 : S22 - S22
  • [46] Phase 1/2 study update of an AAV9-based gene therapy for Gaucher disease type 2 (PROVIDE trial)
    Neuhaus, Sarah
    Lewis, Travis B.
    Tamburri, Paul A.
    Whitley, Chester B.
    Rajan, Deepa
    Gallagher, Renata C.
    Jones, Simon
    Donald, Aimee
    Escolar, Maria L.
    Beckerman, Yael
    Mahoney, Erin
    Hatch, Daniel A.
    Shaughnessy, Lee
    Sondergaard, Patricia
    Uspenskaya, Olga
    Sevigny, Jeffrey
    MOLECULAR GENETICS AND METABOLISM, 2023, 138 (02) : 93 - 93
  • [47] AAV-2 Based Gene Therapy Using Novel Anti-VEGF Molecules for Inhibition of Angiogenesis in the Eye
    Scaria, Abraham
    Pechan, Peter
    Rubin, Hillard
    Lukason, Michael
    Barry, Elizabeth
    Ardinger, Jeffrey
    Qiu, Huawei
    Li, Qiuhong
    Peterson, James
    Hauswirth, William
    Wadsworth, Samuel
    MOLECULAR THERAPY, 2006, 13 : S340 - S340
  • [48] Comparison of AAV serotypes 2 and 5 based vectors for corrective gene therapy for late infantile neuronal ceroid lipofuscinosis
    Giannaris, EL
    De, BP
    Grant, A
    Lam, M
    Peterson, DA
    Sanders, CT
    Hackett, NR
    Sondhi, D
    Kaminsky, SM
    Crystal, RG
    MOLECULAR THERAPY, 2003, 7 (05) : S89 - S89
  • [49] A novel compound heterozygous mutation in AARS2 gene (c.965 G > A, p.R322H; c.334 G > C, p.G112R) identified in a Chinese patient with leukodystrophy involved in brain and spinal cord
    Song, Chengyuan
    Peng, Linliu
    Wang, Shengjun
    Liu, Yiming
    JOURNAL OF HUMAN GENETICS, 2019, 64 (10) : 979 - 983
  • [50] Assessment of Safety of miniMECP2 AAV9 vector (TSHA-102) for Gene-replacement Therapy of Rett Syndrome in Rats
    Prasad, S.
    Flora, G.
    Ramesh, N.
    Newman, M.
    Gray, S. J.
    Sinnett, S.
    Shadu, C.
    HUMAN GENE THERAPY, 2022, 33 (23-24) : A81 - A81
12345